---
title: "P21 (BDNF-mimetic peptide)"
canonical_url: https://peptidelibrary.app/library/p21
description: "Short nootropic peptide associated with Cerebrolysin-derived fragments in research catalogs. Distinct from the p21 CDK inhibitor protein. Not FDA-approved."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# P21 (BDNF-mimetic peptide)

P21 (BDNF-mimetic peptide), also called Cerebrolysin-derived peptide or PRG, is a neurotrophic fragment in the BDNF Stimulator class. P21 is sold as a peptide acting on the brain-derived neurotrophic factor pathway, and the research compound it is usually intended to be is P021, a tetrapeptide derivative of the ciliary neurotrophic factor peptide mimetic developed for tauopathy models.

Short nootropic peptide associated with Cerebrolysin-derived fragments in research catalogs. Distinct from the p21 CDK inhibitor protein. Not FDA-approved.

Also known as: Cerebrolysin-derived peptide, PRG, P21 nootropic.

Categories: Cognitive, Experimental.

## Classification

- Type: Neurotrophic fragment / research
- Mechanism class: BDNF Stimulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

P21 is sold as a peptide acting on the brain-derived neurotrophic factor pathway, and the research compound it is usually intended to be is P021, a tetrapeptide derivative of the ciliary neurotrophic factor peptide mimetic developed for tauopathy models. Preclinical work on P021 describes increased BDNF expression, enhanced neurogenesis in the dentate gyrus, and reduced tau hyperphosphorylation. The important caveat for a reference entry is identity: vendor material sold under the name P21 is not consistently characterised, and the separate and much larger literature on p21 (CDKN1A), a cell-cycle inhibitor protein with no relationship to this peptide, does not apply here. No human trials have been published.

Targets: Neurotrophic signaling (claimed).

Origin: Synthetic research peptide; catalog identity varies.

## Properties

- Molecular formula: C104H157N27O27S
- Molecular weight: ≈2292 g/mol
- Half-life: Unknown (preclinical)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 3
- Latest source: 2019

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Inhibition of AMD-Like Pathology With a Neurotrophic Compound in Aged Rats and 3xTg-AD Mice. Front Aging Neurosci. 2019. 2019. Preclinical: animal or lab study. Population: Female Fisher rats aged 19-21 months, and 3xTg-AD mice. Reduced retinal and macular-degeneration-like pathology. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/31803044/)
2. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017. 2017. Preclinical: animal or lab study. Population: 3xTg-AD mice, treated from approximately 3 months of age. Prevention of dendritic and synaptic deficits and of cognitive impairment. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/28655344/)
3. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014. 2014. Preclinical: animal or lab study. Population: Fisher rats aged 22-24 months. Reduced age-dependent decline in learning and memory, restored neurogenesis, increased BDNF expression, restored cortical and hippocampal synaptic markers. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/24702821/)

## Safety

Side effects: Unknown; Product confusion risk.

Risks: Name collision with CDKN1A/p21 protein.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

P21 (BDNF-mimetic peptide) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is P21 (BDNF-mimetic peptide)?

Short nootropic peptide associated with Cerebrolysin-derived fragments in research catalogs. Distinct from the p21 CDK inhibitor protein. Not FDA-approved.

### How does P21 (BDNF-mimetic peptide) work?

P21 is sold as a peptide acting on the brain-derived neurotrophic factor pathway, and the research compound it is usually intended to be is P021, a tetrapeptide derivative of the ciliary neurotrophic factor peptide mimetic developed for tauopathy models. Preclinical work on P021 describes increased BDNF expression, enhanced neurogenesis in the dentate gyrus, and reduced tau hyperphosphorylation.

### Is P21 (BDNF-mimetic peptide) FDA approved?

No. P21 (BDNF-mimetic peptide) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of P21 (BDNF-mimetic peptide)?

Reported half-life for P21 (BDNF-mimetic peptide) is Unknown (preclinical). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What peptides are similar to P21 (BDNF-mimetic peptide)?

Compounds most often compared with P21 (BDNF-mimetic peptide) include Cerebrolysin, Cortexin, Dihexa and Noopept. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound — Biomolecules, 2022](https://pubmed.ncbi.nlm.nih.gov/36291618/)
- [Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease — Magn Reson Imaging, 2026](https://pubmed.ncbi.nlm.nih.gov/41740658/)
- [Class-level evidence — Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder — J Neurodev Disord, 2024](https://pubmed.ncbi.nlm.nih.gov/39592934/)
- [Class-level evidence — Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound — Alzheimers Res Ther, 2017](https://pubmed.ncbi.nlm.nih.gov/28655344/)
